- Details
- Description
DABRADX (Dabrafenib) is a pharmaceutical product containing dabrafenib, a targeted anticancer medicine that selectively inhibits BRAF kinase. Dabrafenib works by blocking abnormal signaling in cells with specific BRAF mutations, helping to reduce the growth and proliferation of certain cancer cells.
Dabrafenib is used for the treatment of certain cancers associated with BRAF V600 mutations and may be prescribed alone or in combination with trametinib, depending on the specific cancer type and approved indication. It is used in the management of certain forms of melanoma, non-small cell lung cancer, and other BRAF mutation-positive malignancies according to applicable prescribing information and medical guidelines.
DABRADX is intended for oral administration and should be used under the supervision of a qualified healthcare professional. Treatment selection, dosage, duration, monitoring, and combination therapy should be determined by the treating physician based on the patient's condition and the applicable approved indications.
Product strength, packaging, manufacturer, availability, and regulatory status may vary depending on the market and specific product presentation. Healthcare professionals should consult the official product information before use.
